TEHP Stock Overview Operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Avid Bioservices, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Avid Bioservices Historical stock prices Current Share Price US$11.80 52 Week High US$11.80 52 Week Low US$5.35 Beta 1.41 1 Month Change 0.85% 3 Month Change 18.59% 1 Year Change 103.45% 3 Year Change -54.96% 5 Year Change 66.20% Change since IPO -75.92%
Recent News & Updates Punch and Associates Sends Letter to Board of Directors of Avid Bioservices, Inc Nov 15
Funds managed by GHO Capital Partners LLP and Ampersand Management LLC entered into a definitive merger agreement to acquire Avid Bioservices, Inc. (NasdaqCM:CDMO) for approximately $850 million. Nov 08
Funds managed by GHO Capital Partners LLP and Ampersand Management LLC entered into a definitive merger agreement to acquire Avid Bioservices, Inc. (NasdaqCM:CDMO) for approximately $850 million. Nov 07
Avid Bioservices, Inc. Reiterates Earnings Guidance for the Fiscal Year 2025 Sep 11
First quarter 2025 earnings released: US$0.087 loss per share (vs US$0.034 loss in 1Q 2024) Sep 10
Avid Bioservices, Inc. to Report Q1, 2025 Results on Sep 09, 2024 Sep 04 See more updates Punch and Associates Sends Letter to Board of Directors of Avid Bioservices, Inc Nov 15
Funds managed by GHO Capital Partners LLP and Ampersand Management LLC entered into a definitive merger agreement to acquire Avid Bioservices, Inc. (NasdaqCM:CDMO) for approximately $850 million. Nov 08
Funds managed by GHO Capital Partners LLP and Ampersand Management LLC entered into a definitive merger agreement to acquire Avid Bioservices, Inc. (NasdaqCM:CDMO) for approximately $850 million. Nov 07
Avid Bioservices, Inc. Reiterates Earnings Guidance for the Fiscal Year 2025 Sep 11
First quarter 2025 earnings released: US$0.087 loss per share (vs US$0.034 loss in 1Q 2024) Sep 10
Avid Bioservices, Inc. to Report Q1, 2025 Results on Sep 09, 2024 Sep 04
Avid Bioservices, Inc., Annual General Meeting, Oct 16, 2024 Aug 29
New major risk - Share price stability Aug 06
Full year 2024 earnings released: US$2.23 loss per share (vs US$0.004 profit in FY 2023) Jul 05
Avid Bioservices Provides Earnings Guidance for Fiscal Year 2025 Jul 03
Avid Bioservices, Inc. to Report Fiscal Year 2024 Final Results on Jul 02, 2024 Jul 02
Insufficient new directors Jun 12
Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q Mar 21 Avid Bioservices, Inc. announced delayed 10-Q filing Mar 13
Now 30% overvalued after recent price rise Mar 12
Avid Bioservices, Inc. announced that it expects to receive $160 million in funding Mar 08 Avid Bioservices, Inc. announced that it expects to receive $160 million in funding
Now 30% overvalued after recent price rise Feb 14
Insufficient new directors Jan 01
Director recently bought €123k worth of stock Dec 19 Avid Bioservices, Inc. Revises Revenue Guidance for the Full Fiscal Year 2024 Dec 08
New major risk - Share price stability Dec 06
Avid Bioservices, Inc. to Report Q2, 2024 Results on Dec 07, 2023 Dec 01
Now 20% undervalued after recent price drop Oct 19
Independent Chairman recently bought €179k worth of stock Sep 24
Avid Bioservices, Inc. Reiterates Revenue Guidance for Full Fiscal Year 2024 Sep 08
First quarter 2024 earnings released: US$0.033 loss per share (vs US$0.025 profit in 1Q 2023) Sep 08
Avid Bioservices, Inc. to Report Q1, 2024 Results on Sep 07, 2023 Sep 01
Avid Bioservices, Inc., Annual General Meeting, Oct 23, 2023 Aug 29
New minor risk - Profit margin trend Jun 22
Full year 2023 earnings released: EPS: US$0.009 (vs US$2.08 in FY 2022) Jun 22
Avid Bioservices, Inc. to Report Q4, 2023 Results on Jun 21, 2023 Jun 15
Investor sentiment deteriorates as stock falls 16% May 19
Independent Director recently sold €130k worth of stock Apr 13
Third quarter 2023 earnings released: EPS: US$0.007 (vs US$0.036 in 3Q 2022) Mar 15
Investor sentiment deteriorates as stock falls 18% Mar 14
Independent Director recently sold €80k worth of stock Jan 18
Investor sentiment deteriorated over the past week Dec 13
Second quarter 2023 earnings released: US$0.019 loss per share (vs US$0.057 profit in 2Q 2022) Dec 07
Avid Bioservices, Inc. Revises Revenue Guidance for the Full Fiscal Year 2023 Dec 07
Avid Bioservices, Inc. to Report Q2, 2023 Results on Dec 06, 2022 Nov 30
Investor sentiment deteriorated over the past week Nov 08
Investor sentiment deteriorated over the past week Oct 22
Investor sentiment improved over the past week Sep 14
First quarter 2023 earnings released: EPS: US$0.025 (vs US$0.10 in 1Q 2022) Sep 07
Avid Bioservices, Inc. Provides Revenue Guidance for the Fiscal 2023 Sep 07
Avid Bioservices, Inc. to Report Q1, 2023 Results on Sep 06, 2022 Aug 31
Avid Bioservices, Inc., Annual General Meeting, Oct 18, 2022 Aug 30
Investor sentiment improved over the past week Aug 01
Investor sentiment improved over the past week Jul 09
Full year 2022 earnings released: EPS: US$2.08 (vs US$0.057 in FY 2021) Jul 01
Avid Bioservices, Inc. Provides Revenue Guidance for Fiscal 2023 Jun 30
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from Russell 2000 Value Index Jun 26
Avid Bioservices, Inc. to Report Q4, 2022 Results on Jun 29, 2022 Jun 23
Avid Bioservices Announces Launch of Analytical and Process Development Suites Within New, World-Class Viral Vector Development and Manufacturing Facility Jun 15 Avid Bioservices, Inc. Reiterates Revenue Guidance for the Fiscal Year 2022 Mar 10
Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Mar 09
Avid Bioservices, Inc. to Report Q3, 2022 Results on Mar 08, 2022 Mar 03
Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Dec 08
First quarter 2022 earnings released: EPS US$0.10 (vs US$0.058 in 1Q 2021) Sep 09
Independent Director Mark Bamforth has left the company Jul 15
Full year 2021 earnings released: EPS US$0.057 (vs US$0.27 loss in FY 2020) Jun 30
Avid Bioservices, Inc. Provides Revenue Guidance for 2022 Jun 30
Third quarter 2021 earnings released: EPS US$0.013 (vs US$0.063 loss in 3Q 2020) Mar 10
Revenue beats expectations Mar 10
Avid Bioservices, Inc. to Report Q3, 2021 Results on Mar 08, 2021 Mar 02
New 90-day high: €17.10 Mar 01
Avid Bioservices, Inc. Begins Phase 2 of its Myford Manufacturing Capacity Expansion Plan Feb 23 Humanigen and Avid Bioservices Enter into cGMP Manufacturing Agreement for Covid-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing
New 90-day high: €13.60 Feb 02
New 90-day high: €11.80 Jan 15
New 90-day high: €9.50 Dec 23
Second quarter 2021 earnings released: EPS US$0.015 Dec 04
Revenue beats expectations Dec 04
New 90-day high: €8.60 Dec 04
Avid Bioservices, Inc. Increases Revenue Guidance for the Full Fiscal Year 2021 Dec 03
Avid Bioservices, Inc. to Report Q2, 2021 Results on Dec 02, 2020 Nov 25
New 90-day high: €7.30 Nov 14
First quarter earnings released Sep 03
Avid Bioservices, Inc. to Report Q1, 2021 Results on Sep 01, 2020 Aug 26
New 90-day high - €6.75 Aug 13 Shareholder Returns TEHP DE Biotechs DE Market 7D 0.9% -3.5% -2.0% 1Y 103.4% -14.7% 6.9%
See full shareholder returns
Return vs Market: TEHP exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is TEHP's price volatile compared to industry and market? TEHP volatility TEHP Average Weekly Movement 5.2% Biotechs Industry Average Movement 6.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: TEHP has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: TEHP's weekly volatility (5%) has been stable over the past year.
About the Company Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018.
Show more Avid Bioservices, Inc. Fundamentals Summary How do Avid Bioservices's earnings and revenue compare to its market cap? TEHP fundamental statistics Market cap €755.99m Earnings (TTM ) -€146.10m Revenue (TTM ) €144.56m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) TEHP income statement (TTM ) Revenue US$150.45m Cost of Revenue US$138.89m Gross Profit US$11.55m Other Expenses US$163.60m Earnings -US$152.05m
Last Reported Earnings
Oct 31, 2024
Earnings per share (EPS) -2.38 Gross Margin 7.68% Net Profit Margin -101.07% Debt/Equity Ratio 344.0%
How did TEHP perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 02:03 End of Day Share Price 2024/12/23 00:00 Earnings 2024/10/31 Annual Earnings 2024/04/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Avid Bioservices, Inc. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Matthew Hewitt Craig-Hallum Capital Group LLC Vernon Bernardino FBR Capital Markets & Co. Joseph Pantginis H.C. Wainwright & Co.
Show 11 more analysts 
